Nhwa Pharmaceutical has released its 2026 interim report, with net profit attributable to the parent company of 741 million yuan. The company's total operating revenue was 3.218 billion yuan, and net cash flow from operating activities was 280 million yuan, down 43.33 percent from the same period last year. The latest asset-liability ratio was 12.30 percent, and the gross margin was 73.86 percent, down 1.38 percentage points from a year earlier. Return on equity was 8.83 percent, down 0.30 percentage points from a year earlier. Diluted earnings per share were 0.73 yuan, total asset turnover was 0.34 times, and inventory turnover was 1.04 times. The number of shareholders was 53,400, and the top ten shareholders held 588 million shares, accounting for 57.84 percent of total share capital.
Jiangsu Nhwa Pharmaceutical Co LtdInterim report shows net profit of 741M yuan but operating cash flow down 43.33%, mixed signals.
